Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 23, No 36 (December 20), 2005: pp. 9338-9343
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.02.2582

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Santillan, A.
Right arrow Articles by Bristow, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Santillan, A.
Right arrow Articles by Bristow, R. E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Risk of Epithelial Ovarian Cancer Recurrence in Patients With Rising Serum CA-125 Levels Within the Normal Range

Antonio Santillan, Ruchi Garg, Marianna L. Zahurak, Ginger J. Gardner, Robert L. Giuntoli, II, Deborah K. Armstrong, Robert E. Bristow

From the Kelly Gynecology Oncology Service, Johns Hopkins Medical Institutions, Baltimore, MD

Address reprint requests to Antonio Santillan, MD, 600 N Wolfe St, Phipps 281, Baltimore, MD 21287-1281; e-mail: asantil1{at}jhmi.edu

PURPOSE: To evaluate the risk of epithelial ovarian cancer (EOC) recurrence in patients with rising serum cancer antigen 125 (CA-125) levels that remain below the upper limit of normal (< 35 U/mL).

PATIENTS AND METHODS: All patients treated for EOC between September 1997 and March 2003 were identified and screened retrospectively for the following: (1) elevated serum CA-125 at time of diagnosis, (2) complete clinical and radiographic response (CR) to initial treatment with normalization of serum CA-125, (3) at least three serial serum CA-125 determinations that remained within the normal range, and (4) clinical and/or radiographic determination of disease status at the time of last follow-up or recurrence. For statistical analyses, univariate regression models were used to compare absolute and relative changes in CA-125 levels among patients with recurrent disease and those without EOC recurrence.

RESULTS: A total of 39 patients satisfied study inclusion criteria; 22 patients manifested EOC recurrence at a median interval from complete response of 11 months. The median follow-up time from complete response to last contact was 32 months for the 17 patients in the no recurrence group. A relative increase in CA-125 of 100% (odds ratio [OR] = 23.7; 95% CI, 2.9 to 192.5; P = .003) was significantly predictive of recurrence. From baseline CA-125 nadir levels, an absolute increase in CA-125 of 5 U/mL (OR = 8.4; 95% CI, 2.2 to 32.6; P = .002) and 10 U/mL (OR = 71.2; 95% CI, 4.8 to > 999.9; P = .002) were also significantly associated with the likelihood of concurrent disease recurrence.

CONCLUSION: Among patients with EOC in complete clinical remission, a progressive low-level increase in serum CA-125 levels is strongly predictive of disease recurrence.

Supported by The Elizabeth Frost Ovarian Cancer Research Fund.

Presented at the Annual Meeting on Women's Cancer (Society of Gynecologic Oncologists) March 22, 2005, Miami, FL.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Anticancer ResHome page
S. MAHNER, L. WOELBER, S. JUNG, C. Z. EULENBURG, M. IHNEN, J. SCHWARZ, J. SEHOULI, and F. JAENICKE
Prognostic Significance of CA-125 in the Management of Patients with Recurrent Epithelial Ovarian Carcinoma Selected for Secondary Cytoreduction
Anticancer Res, July 1, 2009; 29(7): 2817 - 2821.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
A. Prat, M. Parera, B. Adamo, S. Peralta, M. A. Perez-Benavente, A. Garcia, A. Gil-Moreno, J. M. Martinez-Palones, J. Baselga, and J. M. del Campo
Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels
Ann. Onc., February 1, 2009; 20(2): 294 - 297.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Clin. Chem., December 1, 2008; 54(12): e11 - e79.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. Jackson, R. A. Craven, R. C. Hutson, I. Graze, P. Lueth, R. P. Tonge, J. L. Hartley, J. A. Nickson, S. J. Rayner, C. Johnston, et al.
Proteomic Profiling Identifies Afamin as a Potential Biomarker for Ovarian Cancer
Clin. Cancer Res., December 15, 2007; 13(24): 7370 - 7379.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
P.-Y. Liu, D. S. Alberts, B. J. Monk, M. Brady, J. Moon, and M. Markman
An Early Signal of CA-125 Progression for Ovarian Cancer Patients Receiving Maintenance Treatment After Complete Clinical Response to Primary Therapy
J. Clin. Oncol., August 20, 2007; 25(24): 3615 - 3620.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
B. Y. Karlan and M. McIntosh
The Quest for Ovarian Cancer's Holy Grail: Can CA-125 Still Be the Chalice of Early Detection?
J. Clin. Oncol., April 10, 2007; 25(11): 1303 - 1304.
[Full Text] [PDF]


Home page
JCOHome page
M. Markman
Normal CA-125 and the Risk of Progression in Ovarian Cancer
J. Clin. Oncol., July 10, 2006; 24(20): 3310 - 3310.
[Full Text] [PDF]


Home page
JCOHome page
A. Santillan and R. E. Bristow
In Reply
J. Clin. Oncol., July 10, 2006; 24(20): 3310 - 3311.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online